Hydrix’s FY25 Financials Delay Triggers Trading Halt from October 1

Hydrix Delays FY25 Financial Statements

Hydrix Limited (ASX – HYD), a company known for its innovation in medical technology, has announced a delay in the release of its audited financial statements for the fiscal year ending 30 June 2025. The postponement stems from the need to complete an independent valuation report for its shareholding in Wavewise Analytics Pty Ltd, a key investment held through its subsidiary Hydrix Ventures Pty Ltd.

The company’s auditor has stipulated that this independent valuation is essential to provide sufficient audit evidence to support the valuation of the Wavewise shares. Hydrix promptly engaged an external valuer following this advice, with the valuation report expected to be finalized during the week commencing 6 October 2025.

Implications of the Delay and Trading Suspension

As a direct consequence of this delay, Hydrix will not meet the ASX Listing Rule 4.5.1 deadline to lodge its FY25 financial statements by 30 September 2025. This triggers an automatic suspension of Hydrix shares from trading starting 1 October 2025. The suspension will remain in place until the audited financial statements are lodged, anticipated shortly after the valuation report’s completion.

Importantly, Hydrix has confirmed that aside from this valuation-related audit requirement, there are no other outstanding audit issues or circumstances that might impede the finalization of its financial statements. This suggests the delay is narrowly focused and procedural rather than indicative of broader financial or operational concerns.

Context and Forward Outlook

Hydrix operates across three segments – services that design and engineer innovative products, ventures investing in promising medtech companies, and medical distribution of cardiovascular products. The valuation of Wavewise Analytics shares is a critical component of the ventures segment’s portfolio, and the independent valuation will provide clarity on the investment’s current worth.

Investors will be watching closely for the release of the valuation report and the subsequent audited financial statements, as these documents will shed light on the company’s financial health and the performance of its investments. The trading suspension, while temporary, restricts market access to Hydrix shares and underscores the importance of transparent and timely financial reporting in maintaining investor confidence.